Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Payables (2016 - 2026)

Myriad Genetics has reported Payables over the past 16 years, most recently at $30.0 million for Q4 2025.

  • Quarterly Payables fell 7.12% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, down 7.12% year-over-year, with the annual reading at $30.0 million for FY2025, 7.12% down from the prior year.
  • Payables was $30.0 million for Q4 2025 at Myriad Genetics, down from $31.8 million in the prior quarter.
  • Over five years, Payables peaked at $39.8 million in Q2 2023 and troughed at $15.7 million in Q3 2021.
  • The 5-year median for Payables is $29.6 million (2021), against an average of $29.3 million.
  • Year-over-year, Payables crashed 31.35% in 2021 and then skyrocketed 88.54% in 2022.
  • A 5-year view of Payables shows it stood at $29.6 million in 2021, then fell by 2.7% to $28.8 million in 2022, then dropped by 10.42% to $25.8 million in 2023, then rose by 25.19% to $32.3 million in 2024, then fell by 7.12% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Payables are $30.0 million (Q4 2025), $31.8 million (Q3 2025), and $30.9 million (Q2 2025).